Dual Targeting of Multiple Myeloma Stem Cells and Myeloid-Derived Suppressor Cells for Treatment of Chemotherapy-Resistant Multiple Myeloma
Here we review the insights and lessons learned from early clinical trials of T-cell engaging bispecific antibodies (BsABs) as a new class of biotherapeutic drug candidates with clinical impact potential for the treatment of multiple myeloma (MM). BsABs are capable of redirecting host T-cell cytotox...
Enregistré dans:
Auteur principal: | Fatih M. Uckun |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Frontiers Media S.A.
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/11695cf4ab3a40e68a0db44dd99e9bf0 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Indoleamine 2, 3-Dioxygenase Promotes Aryl Hydrocarbon Receptor-Dependent Differentiation Of Regulatory B Cells in Lung Cancer
par: Sultan Tousif, et autres
Publié: (2021) -
T Cell Bispecific Antibodies: An Antibody-Based Delivery System for Inducing Antitumor Immunity
par: Daisuke Kamakura, et autres
Publié: (2021) -
Role of Extracellular Vesicle-Based Cell-to-Cell Communication in Multiple Myeloma Progression
par: Ilaria Saltarella, et autres
Publié: (2021) -
Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436
par: Fatih M. Uckun, et autres
Publié: (2021) -
Liposomal drug delivery in an in vitro 3D bone marrow model for multiple myeloma
par: Braham MVJ, et autres
Publié: (2018)